We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Rapid Result Test for Complicated Urinary Tract Infections Proves Superior to Standard Urine Culture

By LabMedica International staff writers
Posted on 18 May 2022
Print article
Image: Guidance UTI provides personalized results in less than one day from receipt at lab (Photo courtesy of Pathnostics)
Image: Guidance UTI provides personalized results in less than one day from receipt at lab (Photo courtesy of Pathnostics)

Complicated urinary tract infections (cUTIs) are a significant burden on individual health and healthcare resources that must be diagnosed and treated early and accurately to reduce the risk of poor outcomes. Now, an advanced rapid result test better addresses polymicrobial infections in difficult cases, where bacterial interactions can impact antibiotic resistance.

Pathnostics’ (Irvine, CA, USA) Guidance UTI testing combines PCR and Pooled Antibiotic Susceptibility Testing (P-AST™) for precision diagnostic testing with rapid results for the management of complicated, recurrent or persistent UTIs and elevated risk patients. Guidance UTI provides personalized results in less than one day from receipt at lab, while culture can take 3-5 days, reducing the need for empiric therapy and supporting antibiotic stewardship initiatives. Results are summarized in an easy- to-read report showing therapy options based on the patient’s individual infection.

Real world evidence has shown that Guidance UTI testing is associated with reductions in critical adverse outcomes, healthcare resource utilization and cost for cUTI compared to standard urine culture (SUC). A comparative analysis designed to examine outcomes of one year of cUTI treatment guided by either Guidance UTI or SUC found 44% lower total costs and 77% lower clinically-advanced costs with Guidance UTI versus SUC. The analysis also found that cUTIs in the Guidance UTI cohort were likelier to be managed successfully as outpatients.

"We conducted this analysis because evidence-based testing is of critical importance to diagnostic laboratories in order to improve the quality of patient care and ensure better use of healthcare resources," said Mohit Mathur, SVP of Medical Affairs at Pathnostics. "Our commitment to providing real-world evidence is a key part of our vision to create a new standard of care in UTI testing and our overall mission to pioneer a better future by providing innovative solutions to address diagnostic and therapeutic dilemmas. The findings reinforce the real-world benefits of Guidance UTI's increased sensitivity, reduced time to results, and P-AST results to patients, providers, and the healthcare system."

Related Links:
Pathnostics 

Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Multi-Function Pipetting Platform
apricot PP5
New
Troponin I Test
Quidel Triage Troponin I Test

Print article

Channels

Clinical Chemistry

view channel
Image: The research team has developed the uCR-Chip device to enhance kidney function testing (Photo courtesy of University of Manitoba)

Low-Cost Portable Screening Test to Transform Kidney Disease Detection

Millions of individuals suffer from kidney disease, which often remains undiagnosed until it has reached a critical stage. This silent epidemic not only diminishes the quality of life for those affected... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The UV absorbance spectrometer being used to measure the absorbance spectra of cell culture samples (Photo courtesy of SMART CAMP)

Novel UV and Machine Learning-Aided Method Detects Microbial Contamination in Cell Cultures

Cell therapy holds great potential in treating diseases such as cancers, inflammatory conditions, and chronic degenerative disorders by manipulating or replacing cells to restore function or combat disease.... Read more

Technology

view channel
Image: Schematic illustration of the chip (Photo courtesy of Biosensors and Bioelectronics, DOI: https://doi.org/10.1016/j.bios.2025.117401)

Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples

Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.